{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:13:36Z","timestamp":1791580416241,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110012","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:18:56Z","timestamp":1699989536000},"page":"110012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review"],"prefix":"10.1016","volume":"190","author":[{"given":"Xiaoyong","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110012_b0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2019.6143","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma [published correction appears in JAMA Oncol. 2020 Mar 1;6(3):444]","volume":"6","author":"Molinaro","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0015","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","article-title":"Adult glioblastoma","volume":"35","author":"Alexander","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110012_b0025","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110012_b0030","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/cancers11020174","article-title":"Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A review","volume":"11","author":"Fabian","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.110012_b0035","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial [published correction appears in JAMA. 2018 May 1;319(17):1824]","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2023.110012_b0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2009.10.048","article-title":"Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma","volume":"79","author":"McDonald","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0045","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1186\/s12885-021-08467-3","article-title":"Limited recurrence distance of glioblastoma under modern radiotherapy era","volume":"21","author":"Tu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.110012_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.615368","article-title":"The definition and delineation of the target area of radiotherapy based on the recurrence pattern of glioblastoma after temozolomide chemoradiotherapy","volume":"10","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/neuonc\/nov145","article-title":"Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection","volume":"18","author":"Ringel","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0060","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3171\/2012.9.JNS12504","article-title":"Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article","volume":"117","author":"Bloch","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2023.110012_b0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90\u201305","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0070","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas [published correction appears in J Clin Oncol. 2010 Sep 20;28(27):4280]","volume":"28","author":"Fogh","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.110012_b0120","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0080","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0085","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12885-016-2131-6","article-title":"Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-na\u00efve patients","volume":"16","author":"Jungk","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.110012_b0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12032-018-1198-0","article-title":"Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study","volume":"35","author":"Garcia","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0100","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017387","volume":"7","author":"Roussakow","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.radonc.2023.110012_b0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2023.110012_b0110","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0115","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2015.64.7685","volume":"35","author":"Cloughesy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0125","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnen\/nly022","article-title":"Targetable gene fusions associate with the IDH wild-type astrocytic lineage in adult gliomas","volume":"77","author":"Ferguson","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.radonc.2023.110012_b0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3892\/ol.2022.13632","article-title":"Molecular targeted therapy: A new avenue in glioblastoma treatment","volume":"25","author":"El Atat","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.radonc.2023.110012_b0135","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/j.seminoncol.2014.09.009","article-title":"Response patterns of recurrent glioblastomas treated with tumor-treating fields [published correction appears in Semin Oncol. 2015 Jun;42(3):e44-55]","volume":"41 Suppl 6","author":"Vymazal","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0140","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2023.110012_b0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3390\/cancers11040469","article-title":"Pathological and molecular features of glioblastoma and its peritumoral tissue","volume":"11","author":"D'Alessio","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.110012_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2015.00106","article-title":"Salvage fractionated stereotactic radiotherapy with or without chemotherapy and immunotherapy for recurrent glioblastoma multiforme: A single institution experience","volume":"5","author":"Hasan","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0155","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2009.9.FOCUS09187","article-title":"Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme","volume":"27","author":"Romanelli","year":"2009","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.radonc.2023.110012_b0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3171\/2018.4.JNS172909","article-title":"Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery","volume":"131","author":"Sharma","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2023.110012_b0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1227\/NEU.0000000000001344","article-title":"Indications and efficacy of gamma knife stereotactic radiosurgery for recurrent glioblastoma: 2 decades of institutional experience","volume":"80","author":"Imber","year":"2017","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2023.110012_b0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nec.2020.08.007","article-title":"Radiosurgery for glioblastoma","volume":"32","author":"Bunevicius","year":"2021","journal-title":"Neurosurg Clin N Am"},{"key":"10.1016\/j.radonc.2023.110012_b0175","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.adro.2020.03.022","article-title":"Clinical outcomes in patients with recurrent glioblastoma treated with proton beam therapy reirradiation: Analysis of the multi-institutional proton collaborative group registry","volume":"5","author":"Saeed","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0404.2007.00924.x","article-title":"An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme","volume":"117","author":"Pellettieri","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.radonc.2023.110012_b0185","article-title":"Boron neutron capture therapy for recurrent glioblastoma multiforme: Imaging evaluation of a case with long-term local control and survival","volume":"15","author":"Shimizu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2023.110012_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.addr.2016.09.002","article-title":"Advancements in brachytherapy","volume":"109","author":"Tanderup","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.radonc.2023.110012_b0195","article-title":"The case for brachytherapy: Why it deserves a renaissance","volume":"6","author":"Williams","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0200","doi-asserted-by":"crossref","first-page":"190","DOI":"10.23736\/S1824-4785.21.03370-7","article-title":"Therapeutic applications of radioactive sources: from image-guided brachytherapy to radio-guided surgical resection","volume":"65","author":"Dickhoff","year":"2021","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.110012_b0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12094-012-0759-5","article-title":"Patterns of care for brachytherapy in Europe: updated results for Spain","volume":"14","author":"Guedea","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4103\/jcrt.JCRT_412_17","article-title":"Expert consensus workshop report: Guideline for three-dimensional printing template-assisted computed tomography-guided 125I seeds interstitial implantation brachytherapy","volume":"13","author":"Wang","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.radonc.2023.110012_b0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.zemedi.2021.06.003","article-title":"Multiple direction needle-path planning and inverse dose optimization for robotic low-dose rate brachytherapy","volume":"32","author":"Aum\u00fcller","year":"2022","journal-title":"Z Med Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0220","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ijrobp.2008.12.074","article-title":"Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence","volume":"75","author":"Kleinberg","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13014-020-01586-4","article-title":"A novel three-dimensional template combined with MR-guided 125I brachytherapy for recurrent glioblastoma","volume":"15","author":"He","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0230","doi-asserted-by":"crossref","first-page":"517","DOI":"10.25259\/SNI_494_2021","article-title":"Prospective comparative study of intraoperative balloon electronic brachytherapy versus resection with multidisciplinary adjuvant therapy for recurrent glioblastoma [published correction appears in Surg Neurol Int. 2021 Dec 10;12:607]","volume":"12","author":"Krivoshapkin","year":"2021","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.radonc.2023.110012_b0235","article-title":"GammaTile\u00ae brachytherapy in the treatment of recurrent glioblastomas","volume":"4","author":"Gessler","year":"2021","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.radonc.2023.110012_b0240","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/neuonc\/noac133","article-title":"Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: Results from a prospective trial","volume":"24","author":"Smith","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0245","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11060-014-1595-y","article-title":"Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases","volume":"120","author":"Kickingereder","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.110012_b0250","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00701-015-2550-1","article-title":"Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas","volume":"157","author":"Schwartz","year":"2015","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.radonc.2023.110012_b0255","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0360-3016(89)90518-X","article-title":"Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas","volume":"17","author":"Leibel","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1097-0142(19900701)66:1<27::AID-CNCR2820660106>3.0.CO;2-W","article-title":"Interstitial radiogold implantation for the treatment of recurrent high-grade gliomas","volume":"66","author":"Larson","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110012_b0265","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0360-3016(92)90702-J","article-title":"High activity iodine-125 interstitial implant for gliomas","volume":"24","author":"Scharfen","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0270","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1227\/00006123-199502000-00006","article-title":"Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme","volume":"36","author":"Shrieve","year":"1995","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2023.110012_b0275","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0360-3016(96)80017-4","article-title":"Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas","volume":"35","author":"Halligan","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0280","first-page":"199","article-title":"Concurrent carboplatin and iodine-125 brachytherapy for recurrent glioblastoma multiforme","volume":"11","author":"Chamberlain","year":"1997","journal-title":"Int J Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0355","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0360-3016(98)00494-5","article-title":"Permanent 125iodine implants for recurrent malignant gliomas","volume":"43","author":"Gaspar","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0360","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1259\/bjr.72.860.10624349","article-title":"CT guided interstitial high dose rate brachytherapy for recurrent malignant gliomas","volume":"72","author":"Kolotas","year":"1999","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.110012_b0285","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00006123-200005000-00019","article-title":"Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme","volume":"46","author":"Patel","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2023.110012_b0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0360-3016(01)02804-8","article-title":"Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume","volume":"53","author":"Simon","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0295","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1215\/S1152851703000425","article-title":"Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme","volume":"6","author":"Larson","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0300","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2004.12.032","article-title":"Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy","volume":"62","author":"Chan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0305","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1227\/01.NEU.0000194836.07848.69","article-title":"GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis [published correction appears in Neurosurgery. 2006 Oct;59(4):821]","volume":"58","author":"Gabayan","year":"2006","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2023.110012_b0310","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00066-007-1721-2","article-title":"CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results","volume":"183","author":"Tselis","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.110012_b0315","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3171\/JNS\/2008\/108\/2\/0236","article-title":"Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme","volume":"108","author":"Darakchiev","year":"2008","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2023.110012_b0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1507-1367(10)60077-6","article-title":"Tumour surface area as a prognostic factor in primary and recurrent glioblastoma irradiated with 192Ir implantation","volume":"13","author":"Lebioda","year":"2008","journal-title":"Reports Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2023.110012_b0325","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/2152-7806.103644","article-title":"Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma","volume":"3","author":"Ko","year":"2012","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.radonc.2023.110012_b0330","doi-asserted-by":"crossref","first-page":"e002262","DOI":"10.1136\/bmjopen-2012-002262","article-title":"Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme","volume":"3","author":"Archavlis","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.radonc.2023.110012_b0335","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11060-014-1500-8","article-title":"Combined salvage therapies for recurrent glioblastoma multiforme: evaluation of an interdisciplinary treatment algorithm","volume":"119","author":"Archavlis","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.110012_b0340","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1179\/1743132814Y.0000000398","article-title":"Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy","volume":"36","author":"Archavlis","year":"2014","journal-title":"Neurol Res"},{"key":"10.1016\/j.radonc.2023.110012_b0345","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00066-018-1358-3","article-title":"CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. CT-gest\u00fctzte interstitielle HDR-Brachytherapie bei rezidiviertem Gliobastoma multiforme: 20 Jahre monozentrischer Erfahrung","volume":"194","author":"Chatzikonstantinou","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.110012_b0350","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.brachy.2020.06.013","article-title":"Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control","volume":"19","author":"Wernicke","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2023.110012_b0365","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0042-1749351","article-title":"Updates in the management of recurrent glioblastoma multiforme","volume":"84","author":"Prajapati","year":"2023","journal-title":"J Neurol Surg A Cent Eur Neurosurg"},{"key":"10.1016\/j.radonc.2023.110012_b0370","first-page":"509","article-title":"Outcomes of two types of iodine-125 seed delivery with metal stents in treating malignant biliary obstruction: a systematic review and meta-analysis","volume":"29","author":"Fu","year":"2023","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.radonc.2023.110012_b0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2017.05.023","article-title":"High-dose-rate brachytherapy in the management of operable rectal cancer: A systematic review","volume":"99","author":"Buckley","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0380","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ijrobp.2020.03.004","article-title":"A cost-utility analysis of Magnetic Resonance (MR) guided brachytherapy versus two-dimensional and Computed Tomography (CT) guided brachytherapy for locally advanced cervical cancer","volume":"107","author":"Perdrizet","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0385","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ijrobp.2020.07.2312","article-title":"Phase 2 trial of Accelerated Partial Breast Irradiation (APBI) using Noninvasive Image Guided Breast Brachytherapy (NIBB)","volume":"108","author":"Hepel","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0390","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low-dose-rate prostate brachytherapy: Clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG Oncology\/RTOG 0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0395","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.3390\/cancers13143493","article-title":"Stereotactic ablative brachytherapy: Recent advances in optimization of radiobiological cancer therapy","volume":"13","author":"Xue","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.110012_b0400","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0360-3016(98)00159-X","article-title":"Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma","volume":"41","author":"Laperriere","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110012_b0405","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1227\/00006123-200208000-00009","article-title":"The Brain Tumor Cooperative Group NIH Trial 87\u201301: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine","volume":"51","author":"Selker","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1016\/j.radonc.2023.110012_b0410","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11060-019-03268-y","article-title":"Receipt of brachytherapy is an independent predictor of survival in glioblastoma in the Surveillance, Epidemiology, and End Results database","volume":"145","author":"Bartek","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.110012_b0415","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-013-1139-x","article-title":"Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma","volume":"113","author":"Waters","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2023.110012_b0420","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5114\/jcb.2019.85722","article-title":"Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme","volume":"11","author":"Chatzikonstantinou","year":"2019","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.radonc.2023.110012_b0425","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3171\/2018.7.JNS18656","article-title":"Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas","volume":"131","author":"Brachman","year":"2018","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2023.110012_b0430","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2217\/fon-2020-0558","article-title":"GammaTile\u00ae: Surgically targeted radiation therapy for glioblastomas","volume":"16","author":"Gessler","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.radonc.2023.110012_b0435","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.brachy.2021.08.011","article-title":"Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy","volume":"20","author":"McClelland","year":"2021","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2023.110012_b0440","article-title":"GammaTile brachytherapy combined with external beam radiation therapy for the treatment of a partially resected secondary glioblastoma (WHO Grade 4 IDH-Mutant Astrocytoma): Matching external beam dose gradient to brachytherapy dose fall-off","volume":"13","author":"Peach","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2023.110012_b0445","article-title":"Surviving over a decade with glioblastoma: A clinical course characterized by multiple recurrences, numerous salvage treatments, and novel use of Cesium-131 tiles","volume":"13","author":"Mehta","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2023.110012_b0450","article-title":"Rapid interval recurrence of glioblastoma following gross total resection: A possible indication for GammaTile\u00ae brachytherapy","volume":"13","author":"Easwaran","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2023.110012_b0455","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.brachy.2020.12.005","article-title":"First clinical implementation of GammaTile permanent brain implants after FDA clearance","volume":"20","author":"Ferreira","year":"2021","journal-title":"Brachytherapy"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T04:09:26Z","timestamp":1734235766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":91,"alternative-id":["S0167814023093192"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110012","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brachytherapy is an effective and safe salvage option for re-irradiation in recurrent glioblastoma (rGBM): A systematic review","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110012"}}